Exhibit 99.1
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
New York, NY – September 29, 2025 – MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors.
Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General. He pioneered major innovations in combat casualty care, transfusion medicine, and trauma systems design that saved countless lives and reshaped global health protocols. Post-military, he has continued to drive impact in academic medicine and biotech, with more than 780 peer-reviewed publications, multiple board memberships, and leadership in prehospital blood transfusion programs.
Dr. Holcomb’s appointment comes at a time when Americans face escalating challenges from cancer, rising rates of pulmonary disease, multidrug-resistant infections, and the persistent threat of emerging pandemics. He joins MiNK alongside recently appointed pulmonary critical care expert Dr. Terese Hammond, reinforcing MiNK’s commitment to tackling diseases of profound epidemiologic burden where both patient lives and public health security are at stake.
“We are honored to welcome Dr. Holcomb to the MiNK Board at this transformative stage in our company’s journey,” said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. “John’s unmatched expertise in trauma and surgical critical care medicine, immune activation, and clinical trial execution brings MiNK precisely the kind of insight needed as we advance iNKT cell therapies into late-stage development. His deep experience in building systems of care — from the battlefield to the ICU — and his leadership across global health networks will help us design and deliver programs that address the most pressing challenges. John’s perspective will be instrumental in guiding MiNK toward its next phase of growth, preparedness, and impact.”
“MiNK is advancing iNKT cell therapies with the potential to change how we treat interrelated immune-driven diseases seen on the battlefield and in our acute care hospitals — from trauma and ARDS to multi drug-resistant infections. This unique cellular therapy offers a new approach where current therapies have fallen short, addressing conditions that share common pathways of immune dysregulation. I am eager to help guide MiNK as it brings these breakthroughs closer to patients and strengthens our national preparedness for impending health crises,” said Dr Holcomb.
Dr. Holcomb’s appointment reinforces MiNK’s commitment to clinical rigor and operational excellence as the company continues to scale its therapeutic pipeline and global footprint.